Early recurrence risk stratification of hepatocellular carcinoma receiving preoperative radiotherapy: Incorporating clinical and imaging features across treatment phases

Figure 1 Study population and design. A: Flowchart of patient selection; B: Study schema. HCC: Hepatocellular carcinoma; MRI: Magnetic resonance imaging.

Figure 2 Nomograms based on the prognostic models. A: The baseline-preoperative model; B: The postoperative combined model. GGT: Gamma-glutamyl transpeptidase; APHE: Arterial phase hyperenhancement; AFP: Alpha-fetoprotein; mRECIST: Modified Response Evaluation Criteria in Solid Tumor; CR: Complete response; MVI: Microvascular invasion.

Figure 3 Performance of the prognostic models. A: Time-dependent areas under the curves of the prognostic models at various time points; B: Calibration curves for the baseline-preoperative model for predicting 6-, 12-, and 18-month early recurrence-free survival; C: Calibration curves for the postoperative combined model for predicting 6-, 12-, and 18-month early recurrence-free survival. AUC: Area under the curve.

Figure 4 Kaplan-Meier curves for survival of different risk groups. A: Early recurrence-free survival (≤ 2 years) stratified by the baseline-preoperative nomogram; B: Overall recurrence-free survival stratified by the baseline-preoperative nomogram; C: Overall survival stratified by the baseline-preoperative nomogram; D: Early recurrence-free survival (≤ 2 years) stratified by the postoperative combined nomogram; E: Overall recurrence-free survival stratified by the postoperative combined nomogram; F: Overall survival stratified by the postoperative combined nomogram.